Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

Novo Holdings United Kingdom United States of America

Tenmile and Novo Holdings are core investorsCristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of DirectorsRevagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organismsView original content:https://www.prnewswire.co.uk/news-releases/revagenix-inc-announces-series-b-financing-to-develop-novel-antibiotics-and-additions-to-its-board-of-directors-302027197.html